Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study

Published:January 21, 2013DOI:



      To assess the efficacy of orally administered capsules containing the probiotics Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactogyn, JGL, Rijeka, Croatia) compared to placebo in otherwise healthy women diagnosed with bacterial vaginosis.

      Study design

      Randomized, double-blind, multicentric, placebo-controlled trial, including a total of 544 subjects. Included were women older than 18 years of age, diagnosed with vaginal infection. Subjects received either probiotic (395 subjects or 72.6%) or identical-looking placebo capsules (149 subjects or 27.4%,) per day over a period of 6 weeks. Six and 12 weeks after the beginning of the study, subjects underwent two additional gynecological examinations and their vaginal swabs were evaluated by a clinical cytologist.


      Mean follow-up period after the baseline visit was 44 days. After this period, restitution to balanced vaginal microbiota was reported in 40 subjects (26.9%) in the placebo group, compared to 243 subjects (61.5%) in the probiotic group. Differences between groups were statistically significant at p < 0.001. After the additional 6 weeks of follow up, normal vaginal microbiota were still present in more than half (51.1%) of subjects in the probiotic group, but only in around one-fifth (20.8%) of subjects who were taking placebo (p < 0.001).


      Oral probiotics could be an alternative, side effect-free treatment for one of the most common indications in gynecology, combining the good aspects of both metronidazole and vaginal capsules.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Forsum U.
        • Holst E.
        • Larsson P.G.
        • et al.
        Bacterial vaginosis—a microbiological and immunological enigma.
        APMIS. 2005; 113: 81-90
        • Sweet R.L.
        Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient.
        Infectious Diseases in Obstetrics and Gynecology. 2000; 8: 184-190
        • Ness R.B.
        • Hillier S.L.
        • Kip K.E.
        • et al.
        Bacterial vaginosis and risk of pelvic inflammatory disease.
        Obstetrical and Gynecological Survey. 2005; 60: 99-100
        • Guaschino S.
        • Ricci E.
        • Franch M.
        • et al.
        Treatment of asymptomatic bacterial vaginosis to prevent pre term delivery: a randomized trial.
        European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2003; 110: 149-152
        • Leitich H.
        • Bodner-Adler B.
        • Brunbauer M.
        • Kaider A.
        • Egarter C.
        • Husslein P.
        Bacterial vaginosis as a risk factor for pre-term delivery: a meta analysis.
        American Journal of Obstetrics and Gynecology. 2003; 189: 139-147
        • Eckert L.O.
        • Moore D.E.
        • Patton D.L.
        • et al.
        Relationship of vaginal bacteria and inflammation with conception and early pregnancy loss following in-vitro fertilization.
        Infectious Diseases in Obstetrics and Gynecology. 2003; 11: 11-17
        • Wilson J.D.
        • Ralph S.G.
        • Rutherford A.J.
        Rates of bacterial vaginosis in women undergoing in vitro fertilisation for different types of infertility.
        BJOG. 2002; 109: 714-717
        • Hill G.B.
        • Eschenbach D.A.
        • Holmes K.K.
        Bacteriology of the vagina.
        Scandinavian Journal of Urology and Nephrology. 1984; 86: 23-29
        • Klebanoff S.J.
        • Hillier S.L.
        • Eschenbach D.A.
        • Waltersdorph A.M.
        Control of the microbial flora of the vagina by H202 generating Lactobacilli.
        Journal of Infectious Diseases. 1991; 164: 94-100
        • Eschenbach D.A.
        • Davick P.R.
        • Williams B.L.
        • et al.
        Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis.
        Journal of Clinical Microbiology. 1989; 27: 251-256
        • Anon.
        CDC sexually transmitted disease treatment guidelines 2006.
        Morbidity and Mortality Weekly Report. 2006; 55: 50-52
        • Marrazzo J.M.
        Evolving issues in understanding and treating bacterial vaginosis.
        Expert Review of Anti-Infective Therapy. 2004; 2: 913-922
        • Hager W.D.
        • Rapp R.P.
        Obstetrics and Gynecology Clinics of North America. 1992; 19: 497-510
        • Trexler M.F.
        • Fraser T.G.
        • Jones M.P.
        Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream.
        American Journal of Gastroenterology. 1997; 92: 2112-2113
        • Bradshaw C.S.
        • Morton A.N.
        • Hocking J.
        • et al.
        High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
        Journal of Infectious Diseases. 2006; 193: 1478-1486
        • Reid G.
        • Bruce A.W.
        • Fraser N.
        • et al.
        Oral probiotics can resolve urogenital infections.
        FEMS Immunology and Medical Microbiology. 2001; 30: 49-52
      1. Report of a Joint FAO/WHO Expert Consultation on health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. American Córdoba Park Hotel, Córdoba, Argentina, 1–4 October 2001. [accessed 11.02.08].

        • Morelli L.
        • Zonenenschain D.
        • Del Piano M.
        • Cognein P.
        Utilization of the intestinal tract as a delivery system for urogenital probiotics.
        Journal of Clinical Gastroenterology. 2004; 38: S107-S110
        • Reid G.
        • Burton J.
        Use of lactobacillus to prevent infection by pathogenic bacteria.
        Microbes and Infection. 2002; 4: 319-324
        • Falagas M.E.
        • Betsi G.I.
        • Athanasiou S.
        Probiotics for the treatment of women with bacterial vaginosis.
        Clinical Microbiology and Infection. 2007; 13: 657-664
        • Amsel R.
        • Totten P.A.
        • Spiegel C.A.
        • Chen K.C.
        • Eschenbach D.
        • Holmes K.K.
        Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations.
        American Journal of Medicine. 1983; 74: 14-22
        • Nugent R.P.
        • Krohn M.A.
        • Hillier S.L.
        Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation.
        Journal of Clinical Microbiology. 1991; 29: 297-301
        • Saghaei M.
        Random allocation software for parallel group randomized trials.
        BMC Medical Research Methodology. 2004; 4: 26
        • Anukam K.
        • Osazuwa E.
        • Ahonkhai I.
        • et al.
        Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC14: randomized double blind placebo controlled trial.
        Microbes and Infection. 2006; 8: 1450-1454
      2. Hintze J. PASS 2008. Kaysville, Utah, USA, NCSS, LLC; 2008.

        • Zhang X.J.
        • Shen Q.
        • Wang G.Y.
        • et al.
        Risk factors for reproductive tract infections among married women in rural areas of Anhui Province, China.
        European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2009; 147: 187-191
        • Hellberg D.
        • Nilsson S.
        • Mardh P.A.
        The diagnosis of bacterial vaginosis and vaginal flora changes.
        Archives of Gynecology and Obstetrics. 2001; 265: 11-15
        • Ya W.
        • Reifer C.
        • Miller L.E.
        Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study.
        American Journal of Obstetrics and Gynecology. 2010; 203 (120): e1-e6
        • Boris S.
        • Suarez J.
        • Vazquez F.
        • et al.
        Adherence of human vaginal Lactobacilli to vaginal epithelial cells and interaction with uropathogens.
        Infection and Immunity. 1998; 66: 1985-1989
        • Anukam K.
        • Osazuwa E.
        • Osemene G.I.
        • Ehigiagbe F.
        • Bruce A.W.
        • Reid G.
        Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis.
        Microbes and Infection. 2006; 8: 2772-2776
        • Martinez R.C.
        • Franceschini S.A.
        • Patta M.C.
        • et al.
        Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
        Letters in Applied Microbiology. 2009; 48: 269-274
        • DeLucca P.
        • Raghavarao D.
        Effect of investigator bias on the significance level of the Wilcoxon rank-sum test.
        Biostatistics. 2000; 1: 107-111
        • Oduyebo O.O.
        • Anorlu R.I.
        • Ogunsola F.T.
        The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women.
        Cochrane Database of Systematic Reviews. 2009; : CD006055